LXRX · TickerCove

LXRXLexicon Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $2.02 · now $2.02 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, LXRX has typically landed between $1.46 and $2.88 — a range of −27.6% to +42.4% from the issuance price $2.02.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

4,997 overlapping 1 month windows · 2006-09-26 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.02) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$2.02 · 60% of range

$1.09 low$2.64 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−2.1%

typical move · IQR 25.2%

−27.6%worst (p90)+42.4%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where LXRX has typically landed a month from the 2026-09-16 close of $2.02 — the range is history, not a prediction.

now $2.02 (+0.0%)
typical $1.98 (-2.1%)
middle 50% $1.72–$2.23
90% range $1.46–$2.88

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,997 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2019-07-02	−80.8%	−80.8%	+2.1%
2019-07-01	−80.3%	−80.3%	+0.0%
2019-07-09	−79.9%	−81.2%	+0.0%
3 best
2020-11-09	+186.2%	+0.0%	+186.2%
2020-12-30	+174.6%	+0.0%	+174.6%
2020-11-16	+171.3%	+0.0%	+171.3%

4,997 overlapping windows · 2006-09-26 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

60%

+4.7%

n=20

Feb

50%

−0.8%

n=20

Mar

45%

−2.4%

n=20

Apr

45%

−0.2%

n=20

May

50%

+4.9%

n=20

Jun

65%

+5.6%

n=20

Jul

55%

+3.0%

n=20

Aug

35%

−1.3%

n=20

Sep

40%

+3.8%

n=20

Oct

55%

−1.8%

n=20

Nov

40%

−2.8%

n=20

Dec

35%

+4.1%

n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-02-25	DEBBANE RAYMOND	director	Purchase	2,000 @ $1.49	$3K	+0.1% of holding	+15.3%	+42.9%	1,906,186	Form 4 · filed 2 days after the trade
2026-02-23	DEBBANE RAYMOND	director	Purchase	100,000 @ $1.47	$147K	+5.5% of holding	+17.9%	+41.2%	1,904,186	Form 4 · filed 2 days after the trade
2026-02-20	DEBBANE RAYMOND	director	Purchase	100,000 @ $1.48	$148K	+5.9% of holding	+16.2%	+44.8%	1,804,186	Form 4 · filed 3 days after the trade
2026-02-19	DEBBANE RAYMOND	director	Purchase	50,000 @ $1.44	$72K	+3.0% of holding	+7.6%	+31.4%	1,704,186	Form 4 · filed 4 days after the trade
2026-02-18	DEBBANE RAYMOND	director	Purchase	133,688 @ $1.32	$176K	+8.8% of holding	+26.6%	+69.9%	1,654,186	Form 4 · filed same day
2026-02-17	DEBBANE RAYMOND	director	Purchase	76,857 @ $1.31	$101K	+5.3% of holding	+21.3%	+70.3%	1,520,498	Form 4 · filed 1 day after the trade
2026-02-13	DEBBANE RAYMOND	director	Purchase	57,952 @ $1.31	$76K	+4.2% of holding	+25.3%	+64.7%	1,443,641	Form 4 · filed 5 days after the trade
2026-02-02	Invus Global Management, LLC	director	Purchase	1,538,462 @ $1.30	$2.0M	ownership Δ n/a	+31.9%	+87.7%	1,538,462	Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

247 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-06-03	Amouyal Philippe	director	Option exercise	89,312	0	Form 4
2026-06-03	BARKER SAM L	director	Option exercise	89,312	213,771	Form 4
2026-06-03	BARKER SAM L	director	Option exercise	89,312	0	Form 4
2026-06-03	Cheung Ivan	director	Option exercise	89,312	89,312	Form 4
2026-06-03	Cheung Ivan	director	Option exercise	89,312	0	Form 4
2026-06-03	DEBBANE RAYMOND	director	Option exercise	89,312	1,995,498	Form 4
2026-06-03	DEBBANE RAYMOND	director	Option exercise	89,312	0	Form 4
2026-06-03	SOBECKI CHRISTOPHER J	director	Option exercise	89,312	293,177	Form 4
2026-06-03	SOBECKI CHRISTOPHER J	director	Option exercise	89,312	0	Form 4
2026-06-03	Sullivan Diane E.	director	Option exercise	89,312	126,122	Form 4
2026-06-03	Sullivan Diane E.	director	Option exercise	89,312	0	Form 4
2026-06-03	Swain Judith L	director	Option exercise	89,312	174,486	Form 4
2026-06-03	Swain Judith L	director	Option exercise	89,312	0	Form 4
2026-06-03	Amouyal Philippe	director	Option exercise	89,312	374,486	Form 4
2026-05-01	Amouyal Philippe	director	Award / grant	43,478	43,478	Form 4
2026-05-01	Swain Judith L	director	Award / grant	35,714	35,714	Form 4
2026-05-01	Swain Judith L	director	Award / grant	43,478	43,478	Form 4
2026-05-01	Sullivan Diane E.	director	Award / grant	35,714	35,714	Form 4
2026-05-01	Sullivan Diane E.	director	Award / grant	43,478	43,478	Form 4
2026-05-01	DEBBANE RAYMOND	director	Award / grant	35,714	35,714	Form 4
2026-05-01	DEBBANE RAYMOND	director	Award / grant	43,478	43,478	Form 4
2026-05-01	Cheung Ivan	director	Award / grant	35,714	35,714	Form 4
2026-05-01	Cheung Ivan	director	Award / grant	43,478	43,478	Form 4
2026-05-01	BARKER SAM L	director	Award / grant	35,714	35,714	Form 4
2026-05-01	BARKER SAM L	director	Award / grant	43,478	43,478	Form 4
2026-05-01	SOBECKI CHRISTOPHER J	director	Award / grant	35,714	35,714	Form 4
2026-05-01	SOBECKI CHRISTOPHER J	director	Award / grant	43,478	43,478	Form 4
2026-05-01	Amouyal Philippe	director	Award / grant	35,714	35,714	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Option exercise	20,421,735	175,156,062	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Option exercise	408,435	0	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-04-30	Artal Participations S.a r.l.	director	Award / grant	408,435	408,435	Form 4
2026-02-28	Exton Michael	director	Withheld for tax	204,831	298,432	Form 4
2026-02-28	Granowitz Craig B	officer	Withheld for tax	109,098	323,430	Form 4
2026-02-28	Crum Brian T	officer	Withheld for tax	105,019	428,802	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i